Innovative Medicines Initiative

Innovative Medicines Initiative projects are using advanced computational analysis, human cell lines and tissues, and better models to ‘reduce, replace and refine’ the use of animals in research.

Induced pluripotent stem cells are important research tools, but making and sharing them is far from easy. IMI’s EBiSC project has created a research infrastructure offering scientists a range of cell lines plus relevant advice and guidance.

The Innovative Medicines Initiative is a catalyst, and our research has been a launch pad for vital research infrastructures that will drive innovation long after projects have finished, writes IMI director Pierre Meulien.

IMI Associated Partner the TB Alliance values the way IMI brings together the main players, makes available resources, and creates a platform for collaboration with the industry, academia and the public sector.

Respiratory syncytial virus (RSV) still claims millions of mostly infant victims every year. IMI’s RESCEU project has put together the most comprehensive cache of evidence to date on the true burden of the disease.

IMI projects Mobilise-D and IDEA-FAST have launched the Digital Health Catalyst to train and support researchers, clinicians and other professionals in the fast-moving digital health field.

When developing drugs for osteoarthritis, it’s hard to find the right people for clinical trials. IMI’s APPROACH project found that machine learning models do better at this than traditional methods.

The Innovative Medicines Initiative project ZAPI has put in place a new pan-virus methodology for ramping up the production of new vaccines in the next crisis

As COVID-19 shows, older people are particularly vulnerable to infectious diseases. IMI’s VITAL project is studying vaccines and immunity in older adults, to figure out the best strategies to keep people healthier for longer.

Data on the safety and immunogenicity of the technology behind the Johnson & Johnson COVID-19 vaccine was gathered during IMI-supported clinical studies into the company’s Ebola vaccine.